News ESMO26: 'Unprecedented' results from DeLLphi-305 in SCLC Amgen has revealed data that it hopes will move its DLL3-targeting T-cell engager Imdelltra into the first-line setting in small cell lung cancer.
News ESMO26: VOLGA stirs up perioperative bladder cancer therapy The VOLGA trial shows that Imfinzi and Padcev could be a rival Keytruda+Padcev in perioperative treatment of muscle-invasive bladder cancer.
News ESMO26: Neoadjuvant Enhertu fails in early breast cancer AstraZeneca and Daiichi Sankyo's Enhertu failed to show efficacy as neoadjuvant therapy for early-stage HER2-low breast cancer in the TALENT trial.
News AZ grabs FDA nod for Ultomiris in rare kidney disease IgAN AstraZeneca has staked a claim to the increasingly crowded IgAN market with an accelerated approval from the FDA for Ultomiris, its fifth indication.
News AZ and Oracle team up on AI platform for clinical trials AstraZeneca has launched a project with tech giant Oracle that will use AI and real-world data to improve clinical research and patient care.
News AI in drug discovery & development: News watch, October 2026 Recent news in biopharma AI include a $1.5bn partnership between AstraZeneca and insitro, plus news from Iambic, DaltonTx, NVIDIA, and Chai Discovery.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.